Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data.
Nom du journal : JCO Precis Oncol
Année : 2023
Volume : 7
Page de départ : e2200436
